Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 882 matching trials from the live ClinicalTrials.gov search.
Conditions
Migraine, Fibromyalgia, Conditioned Pain Modulation
Interventions
Remote Electrical Neuromodulation (REN) device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bridgewater, New Jersey
Active, not recruiting Not applicable Interventional

Mobile Subthreshold Exercise Program for Concussion--R01

NCT04688255
Conditions
Concussion, Brain, Concussion, Mild, Brain Injuries, Traumatic, Persistent Post Traumatic Headache, Post-Concussion Syndrome, Post-Concussive Syndrome, Chronic
Interventions
MSTEP, Stretching
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Not applicable Interventional

MMA Embolization for Refractory Chronic Migraine

NCT06735833
Conditions
Migraine Disorders
Interventions
Middle Meningeal Artery embolization
Device
Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Walnut Creek, California • Hartford, Connecticut • Buffalo, New York + 5 more
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
93
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 86 more
Conditions
Migraine, Sinusitis
Interventions
almotriptan or pseudoephedrine
Drug
Lead sponsor
Clinvest
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Springfield, Missouri
Conditions
Temporomandibular Disorder, Orofacial Pain
Interventions
Nerivio treatment
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Newark, Delaware • Ridgeland, Mississippi • Commack, New York + 1 more
Conditions
Migraine
Interventions
Erenumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
42
States / cities
Huntsville, Alabama • Phoenix, Arizona • Fullerton, California + 38 more
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
90
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more
Conditions
Medication Overuse Headache
Interventions
DFN-11 Injection
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Springfield, Missouri
Conditions
Migraine
Interventions
Ubrogepant, Erenumab, Galcanezumab
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Springfield, Missouri • West Bend, Wisconsin
Not listed Not applicable Interventional

AVPI Migraine Study

NCT05537818
Conditions
Migraine
Interventions
AVPI Device
Device
Lead sponsor
Nocira, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Saint Charles, Missouri • Springfield, Missouri
Conditions
Migraine
Interventions
Timolol, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Migraine
Interventions
Frovatriptan, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Posttraumatic Headache, Mild Traumatic Brain Injury
Interventions
Erenumab 140 Mg/mL Subcutaneous Solution, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Fort Bragg, North Carolina • Pittsburgh, Pennsylvania • El Paso, Texas + 1 more
Conditions
Migraine, Episodic Migraine, Headache, Headache, Migraine
Interventions
ReMMi-D Digital Therapeutic
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2951742 in Healthy Japanese and Caucasian Participants

NCT02104765
Conditions
Migraine Disorders
Interventions
LY2951742, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cypress, California
Conditions
Acute Treatment of Migraine
Interventions
Zavegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Hinesville, Georgia • Minneapolis, Minnesota + 9 more
Conditions
Headache, Intranasal Ketamine
Interventions
Ketamine, Normal saline, Metoclopramide, Ketorolac, Dexamethasone, Benadryl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Migraine
Interventions
BHV-3500 (zavegepant), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
116
States / cities
Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 88 more
Recruiting No phase listed Observational

Emgality for Migraine in Breastmilk

NCT06085144
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Migraine, Major Depressive Disorder
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
Conditions
Migraine
Interventions
AXS-07 (meloxicam-rizatriptan)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
31
States / cities
Colton, California • Fullerton, California • La Jolla, California + 28 more
Conditions
Migraine
Interventions
Rimegepant, Triptans
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Conditions
Migraines, Bleeding, Spotting
Interventions
frovatriptan, placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas